Prolong Adjuvant Aromatase Inhibitor Therapy in Breast Cancer?

Video
Conference|San Antonio Breast Cancer Symposium (SABCS)

Cancer Network spoke with Richard Gray, MSc, about the effects of prolonging adjuvant aromatase inhibitor therapy has on breast cancer patients.

Cancer Network spoke with Richard Gray, MSc, about the effects of prolonging adjuvant aromatase inhibitor therapy has on breast cancer patients.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content
A statistically significant difference was observed between the 2 groups in patients who received second-line therapy.

Cisplatin/Carboplatin Plus Etoposide Yield Similar Real-World Efficacy in ES-SCLC

Tim Cortese
September 17th 2025
Article
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
September 17th 2025
Podcast
Numerically higher ORRs were reported in those who received treatment in the second line vs third line, in those with a CTFI of 90 days or more, and those without CNS metastasis.

Lurbinectedin Yields Responses in Various ES-SCLC Subgroups

Tim Cortese
September 17th 2025
Article
Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
September 17th 2025
Podcast
All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.

Surufatinib Combo Displays Promising Efficacy in Frontline ES-SCLC

Roman Fabbricatore
September 17th 2025
Article
The second takeaway is that the type of responses and efficacy that we have seen with these combinations rival what we have in our standard of care armamentarium.

How Promising Are Immunotherapy Combos in Indolent Lymphoma?

Tim Cortese
September 17th 2025
Article